TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”) today announced that they have entered into a method development agreement with Isis Pharmaceuticals (Isis) to develop a multiplexed assay that will utilize SQI’s Ig_PLEX™ multiplexing immunogenicity technology.
“SQI is excited to develop a unique multiplex anti-drug antibody assay for Isis as a first step to further the potential commercial relationship between the two organizations,” said Andrew Morris, CEO of SQI Diagnostics. “We believe that our multiplexing solutions and services are highly complementary with Isis’ extensive portfolio of drugs under development.”
The potential benefits to drug development companies using SQI’s Ig_PLEX tests in their clinical studies include providing quantitative results for multiple anti-drug antibody isotypes in a single test, utilizing SQI’s automated systems to significantly improve the many benefits of multiplexing during drug development’s immunogenicity testing phase, and getting ahead of the emerging regulatory guidelines surrounding immunogenicity testing worldwide.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “is subject to” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage, and our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.